{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:37:29Z","timestamp":1783633049061,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Recently, selpercatinib, a highly selective inhibitor of RET receptor tyrosine kinase, has been used for RET-altered thyroid cancer. We present four cases of patients with advanced thyroid cancer who were treated with selpercatinib. The first patient was a 63-year-old male with advanced medullary thyroid cancer (MTC) treated with vandetanib. Six months ago, he had an intracranial hemorrhage and swallowing difficulty. He started selpercatinib with percutaneous endoscopic gastrostomy (PEG). For 11 months, a partial response (PR) was observed stably with PEG administration without any more cardiovascular events. The second patient was a 67-year-old female with advanced MTC treated with vandetatib. After selpercatinib treatment, a PR was observed for most metastatic sites, including choroidal metastasis. The third patient was a 32-year-old female with advanced papillary thyroid cancer (PTC) without history of systematic treatment. For six months, a PR was observed at her metastatic site with manageable adverse events. The last patient was a 59-year-old female with advanced PTC treated with lenvatinib. She suffered from a panic disorder and pleural pain due to metastasis during lenvatinib treatment. After selpercatinib treatment, her pain and panic symptoms were improved. Facing varying clinical obstacles of the real world, selpercatinib safely proved remarkable therapeutic efficacy regardless of previous treatment or metastatic site.<\/jats:p>","DOI":"10.3390\/curroncol30030229","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T06:45:08Z","timestamp":1678085108000},"page":"3020-3031","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea"],"prefix":"10.3390","volume":"30","author":[{"given":"Han-Sang","family":"Baek","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-7135","authenticated-orcid":false,"given":"Jeonghoon","family":"Ha","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunggyun","family":"Ha","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Seong","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-3708","authenticated-orcid":false,"given":"Chan Kwon","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-6482","authenticated-orcid":false,"given":"Dong-Jun","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ji, J.H., Oh, Y.L., Hong, M., Yun, J.W., Lee, H.W., Kim, D., Ji, Y., Kim, D.H., Park, W.Y., and Shin, H.T. (2015). Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1005467"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e144847","DOI":"10.1172\/JCI144847","article-title":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3803\/EnM.2020.687","article-title":"Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17588359221119318","DOI":"10.1177\/17588359221119318","article-title":"Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: Results from the phase II LIBRETTO-321 study","volume":"14","author":"Zheng","year":"2022","journal-title":"Ther Adv. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1210\/clinem\/dgac325","article-title":"Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib","volume":"107","author":"Elisei","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1\u2014Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_16","unstructured":"Eli Lilly and Company USA, Ltd. (2022, February 27). Retevmo (Selpercatinib). Prescribing Information. Available online: https:\/\/pi.lilly.com\/us\/retevmo-uspi.pdf."},{"key":"ref_17","first-page":"8657914","article-title":"A Novel RET D898Y Germline Mutation in a Patient with Pheochromocytoma","volume":"2018","author":"Yi","year":"2018","journal-title":"Case Rep. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art Strategies for Targeting RET-Dependent Cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.annonc.2021.08.1987","article-title":"Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: A case report","volume":"32","author":"Matrone","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2174\/1389450119666180213102939","article-title":"Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review","volume":"19","author":"Facchinetti","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41571-020-0384-0","article-title":"Histology-agnostic drug development\u2014Considering issues beyond the tissue","volume":"17","author":"Pestana","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in Patients with RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy from the Registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"677892","DOI":"10.3389\/fonc.2021.677892","article-title":"Next-Generation Sequencing Enhances the Diagnosis Efficiency in Thyroid Nodules","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/his.12461","article-title":"Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology","volume":"66","author":"Blanchard","year":"2015","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/thy.2021.0542","article-title":"Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers","volume":"32","author":"Ma","year":"2022","journal-title":"Thyroid"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","article-title":"Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"v475","DOI":"10.1093\/annonc\/mdx380.035","article-title":"1333P\u2014Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project: LC-SCRUM-Japan","volume":"28","author":"Usui","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17588359211019675","DOI":"10.1177\/17588359211019675","article-title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): A retrospective analysis of patients treated through an access program","volume":"13","author":"Illini","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41598-021-04659-w","article-title":"Thyroid hormones regulate cardiac repolarization and QT-interval related gene expression in hiPSC cardiomyocytes","volume":"12","author":"Ulivieri","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83.e1","DOI":"10.1016\/j.genhosppsych.2010.09.008","article-title":"Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases","volume":"33","author":"Schellekens","year":"2011","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/annonc\/mdm455","article-title":"Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy","volume":"18","author":"Hoekman","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief Report: Chylothorax and Chylous Ascites during RET Tyrosine Kinase Inhibitor Therapy","volume":"17","author":"Falcon","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1530\/EJE-22-0643","article-title":"Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib","volume":"187","author":"Prete","year":"2022","journal-title":"Eur. J. Endocrinol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:47:09Z","timestamp":1760122029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["curroncol30030229"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30030229","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}